Unique ID issued by UMIN | UMIN000004650 |
---|---|
Receipt number | R000005541 |
Scientific Title | Evaluation of Usefulness of ONS (Oral Nutritional Supplement) in Postoperative Patients with Gastric Cancer |
Date of disclosure of the study information | 2010/12/01 |
Last modified on | 2014/08/29 09:17:55 |
Evaluation of Usefulness of ONS (Oral Nutritional Supplement) in Postoperative Patients with Gastric Cancer
Evaluation of Usefulness of ONS (Oral Nutritional Supplement) in Postoperative Patients with Gastric Cancer
Evaluation of Usefulness of ONS (Oral Nutritional Supplement) in Postoperative Patients with Gastric Cancer
Evaluation of Usefulness of ONS (Oral Nutritional Supplement) in Postoperative Patients with Gastric Cancer
Japan | Asia(except Japan) |
gastric cancer
Surgery in general | Gastrointestinal surgery |
Malignancy
NO
To determine whether ONS is of clinical significance (effect to general condition) in patients for whom total gastrectomy and distal gastrectomy for cancer is indicated.
Efficacy
Percent change and amount of change in body weight (amount of change in BMI)
1)Percent change and amount of change in grip strength
2)QOL (EORTC QLQ-C30)
3)Percentage of completed chemotherapy (only patients receiving chemotherapy)
4)Nutritional indexes
5)Body composition
6)Occurrence of adverse events of ONS
Interventional
Parallel
Randomized
Open -no one is blinded
Active
YES
NO
Institution is considered as a block.
YES
Central registration
2
Treatment
Food |
Postoperatively, intervention with ONS at a dose of approximately 400 kcal/day will be administered and observed from the start of meal to 12 weeks after discharge.
We assess a control group in the same way for 12 weeks.
20 | years-old | <= |
Not applicable |
Male and Female
1)Male or female patients aged 20 years and older at the time of informed consent
2)Patients who are able to take orally
3)Patients who will receive radical total gastrectomy for cancer irrespective of technique
4) Patients who will receive radical distal gastrectomy for cancer irrespective of technique
4)Patients who have not received pretreatment for gastric cancer (radiation, chemotherapy, and hormonal therapy etc.)
5)Patients who fully understand the study procedures and have given voluntary written informed consent after a full explanation is given
1)Patients with ileus
2)Patients with no residual intestinal function
3)Patients with severe liver disorder
AST (GOT) or ALT (GPT) ≥ 2.5 times the upper limit of normal at hospital
4)Patients with severe renal disorder
Cr ≥ 2.0 mg/dL
5)Patients with abnormal glucose metabolism such as severe diabetes mellitus : HbA1c ≥ 7.0%
6)Patients with allergy to any ingredient of milk, wheat, soy bean, or salmon
7)Pregnant women, women suspected of being pregnant, or lactating women
8)Patients with active double cancer and/or multiple cancer
150
1st name | |
Middle name | |
Last name | SETO, Yasuyuki |
THE UNIVERSITOY OF TOKYO
Department of Gastrointestinal Surgery
7-3-1, Hongo, Bunkyo-ku, Tokyo
03-3815-5411
seto-tky@umin.ac.jp
1st name | |
Middle name | |
Last name | HATAO, Fumihiko |
THE UNIVERSITOY OF TOKYO
Department of Gastrointestinal Surgery
7-3-1, Hongo, Bunkyo-ku, Tokyo
03-3815-5411
fchobi@gmail.com
THE UNIVERSITOY OF TOKYO
EN Otsuka Pharmaceutical CO., LTD.
Profit organization
NO
2010 | Year | 12 | Month | 01 | Day |
Unpublished
Completed
2010 | Year | 11 | Month | 01 | Day |
2010 | Year | 12 | Month | 01 | Day |
2015 | Year | 12 | Month | 01 | Day |
2010 | Year | 12 | Month | 01 | Day |
2014 | Year | 08 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005541
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |